Illumina has teamed up with AB Sciex to add proteomic data analysis capabilities to its BaseSpace platform. As a result of the collaboration, Illumina is hosting four apps for processing, analyzing and visualizing proteomics mass spectrometry data on BaseSpace.
The National Institutes of Health has forged 7 research agreements with academic and industry partners aimed at identifying new adjuvant candidates that could be used in vaccines to boost immune responses against various pathogens.
A novel treatment made by tiny Mapp Biopharmaceutical may be the key to beating back West Africa's Ebola outbreak, but despite the support of the U.S. government and some of the world's largest charities, producing enough to counter the spread will be difficult.
On Wednesday, Pfizer and Bristol-Myers Squibb got some positive data on an undo med for their market trailer, Eliquis. And that antidote could be on the way in the not-too-distant future.
Transparency Market Research predicts that the worldwide implantable drug delivery market will reach $21.1 billion by 2018.
A pill coated with tiny needles may help improve oral treatments, according to researchers. When swallowed, the pill delivers large molecules such as insulin into the lining of the stomach and does so more efficiently than an injection under the skin.
Finding the right delivery vehicle for a drug, one that will let the drug reach its full potential, is an invaluable prospect. And now MIT engineers have developed a way to test these vehicles quickly in vivo to determine which of them will be most efficient in delivering its payload.
French pharma giant Sanofi has unveiled plans to bring together the drug development work being done in a dozen different Pacific Rim countries, creating a major new R&D center in Shanghai that will employ 1,400 staffers.
Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.
RNAi leader Alnylam, the American Porphyria Consortium and The European Porphyria Network are launching the Explore observational study of patients with the rare disease, with the hope of advancing Alnylam's candidate for porphyria, with a goal of filing for approval in late 2014 or early 2015.